Augmenting Excipient Functionality - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Augmenting Excipient Functionality


Pharmaceutical Technology
Volume 34, Issue 7, pp. 48-52


Patricia Van Arnum
Excipients play an important part in a pharmaceutical formulations and finished drug products. Like other sectors in the pharmaceutical–ingredient value chain, excipient manufacturers are addressing product demand and technical challenges in formulation development and manufacturing through product and service enhancements, capacity expansions, and select acquisitions. These changes are occurring as relative moderate growth is projected for the global excipients market.

Crunching the numbers

The global excipients market was valued at $3.5 billion in 2006, according to an analysis by BCC Research. The market is expected to increase at a compound annual growth rate (CAGR) of 3.8% through 2011, when it will reach $4.3 billion. The global excipients market is broken down into three major segments: organic chemicals, inorganic chemicals, and United States Pharmacopeia (USP)-grade water (1).


(IMage: KATHLEEN BRENNAN, BRAND X PICTURES, GETTY IMAGES)
Carbohydrates represent the largest share of global organic excipients on a value basis, followed by petrochemicals, oleochemicals, and proteins. Carbohydrates account for 39%, or $1.2 billion, of the global organic excipient market, based on 2006 data. Petrochemicals account for 30.3%, or $941 million. Glycols and povidones are the leading petrochemical excipients. Oleochemicals account for 28.3%, or $880 million. Proteins represent a small percentage, only 2.2%, or $68 million, according to BCC. (1).

Inorganic chemicals used as pharmaceutical excipients include calcium salts, halites, metal oxides, and silicates. Calcium salts hold 73.2%, or $266 million, of the global inorganic excipients market, according to BCC. Halites and metal oxides each comprise 8.5%, or $31 million, of the global market for inorganic excipients. Silicates account for 4.8%, or $17 million, of the global market for inorganic excipients. Other inorganic excipients account for 5%, or $18 million, according to BCC (1).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here